#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	6884	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2735	585.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	2031	2031	T	887	T,C,A	746,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	6884	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2735	585.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1765	1765	C	874	C,A,G,T	745,6,3,3	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	11554	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4068	653.8	0	.	n	.	0	A9G	SNP	9	9	A	731	731	G	880	G,A	767,5	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	11554	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4068	653.8	0	.	n	.	0	T695C	SNP	695	695	T	1417	1417	C	861	C,A,T	703,4,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	11554	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4068	653.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2693	2693	C	826	C,G,T	700,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	11554	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4068	653.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2767	2767	A	823	A	696	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	11554	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4068	653.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3319	3319	C	798	C,T	679,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	568	folP	855	855	99.88	folP.l6.c4.ctg.1	2189	60.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1454	1456	AGC	93;93;93	A;G;C	80;81;80	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1390	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3982	82.6	0	.	p	.	0	T243I	NONSYN	727	729	ACA	1411	1413	ATA	125;122;115	A;T,C,A;A	112;108,1,2;103	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1390	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3982	82.6	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1432	1434	ATA	124;124;124	A;T;A,G	112;112;110,1	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1390	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3982	82.6	1	SNP	p	S91F	0	.	.	271	273	TCC	955	957	TCC	104;104;104	T;C;C	82;87;88	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1390	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3982	82.6	1	SNP	p	D95N	0	.	.	283	285	GAC	967	969	GAC	105;105;105	G,C;A,G;C,G	85,1;84,1;88,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1390	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3982	82.6	1	SNP	p	D95G	0	.	.	283	285	GAC	967	969	GAC	105;105;105	G,C;A,G;C,G	85,1;84,1;88,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	402	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1380	67.1	0	.	p	.	0	T169P	NONSYN	505	507	ACG	890	892	CCG	90;90;90	C,A;C,G;G,T	79,2;79,1;78,1	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	402	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1380	67.1	1	SNP	p	G45D	0	.	.	133	135	GGC	518	520	GGC	122;122;120	G;G;C	106;99;102	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	282	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1425	43.3	0	.	n	.	0	.206T	INS	206	206	T	878	878	T	98	T	85	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	667	1228	parC	2304	2304	99.74	parC.l6.c17.ctg.1	3553	80.8	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1947	1949	GCC	100;99;95	G;C;C,G	91;90;82,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	667	1228	parC	2304	2304	99.74	parC.l6.c17.ctg.1	3553	80.8	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1989	1991	GCA	106;108;108	G;C;A	94;91;88	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	667	1228	parC	2304	2304	99.74	parC.l6.c17.ctg.1	3553	80.8	1	SNP	p	D86N	0	.	.	256	258	GAC	942	944	GAC	86;86;87	G,C;A,G;C	69,1;52,1;64	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	667	1228	parC	2304	2304	99.74	parC.l6.c17.ctg.1	3553	80.8	1	SNP	p	S87R	0	.	.	259	261	AGT	945	947	AGT	87;89;93	A;G;T,G	63;68;71,2	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	667	1228	parC	2304	2304	99.74	parC.l6.c17.ctg.1	3553	80.8	1	SNP	p	S87W	0	.	.	259	261	AGT	945	947	AGT	87;89;93	A;G;T,G	63;68;71,2	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	667	1228	parC	2304	2304	99.74	parC.l6.c17.ctg.1	3553	80.8	1	SNP	p	S87I	0	.	.	259	261	AGT	945	947	AGT	87;89;93	A;G;T,G	63;68;71,2	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	667	1228	parC	2304	2304	99.74	parC.l6.c17.ctg.1	3553	80.8	1	SNP	p	S88P	0	.	.	262	264	TCC	948	950	TCC	93;93;94	T,G;C,T;C	75,1;75,2;79	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	667	1228	parC	2304	2304	99.74	parC.l6.c17.ctg.1	3553	80.8	0	HET	.	.	.	T1526G	.	1526	1526	T	2212	2212	T	69	T,G	55,7	.	.
parE.WHO_W_01411c	parE.WHO_W_01411c	1	1	27	1348	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3475	91.9	1	SNP	p	G410V	0	.	.	1228	1230	GGT	2000	2002	GGT	90;91;91	G;G;T,G	79;75;70,3	parE.WHO_W_01411c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	1344	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2678	115.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1641	1643	GCA	193;195;196	G;C;A,C	165;167;163,1	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1344	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2678	115.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1644	1646	ATC	196;196;194	A;T,G;C	168;171,2;170	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1344	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2678	115.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1656	1658	GTG	195;195;195	G,C;T;G	169,1;166;171	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1344	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2678	115.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1656	1658	GTG	195;195;195	G,C;T;G	169,1;166;171	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1344	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2678	115.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2160	2162	ACC	133;135;133	A;C;C	95;106;113	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1344	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2678	115.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2214	2216	GCG	118;126;126	G;C;G,T	102;99;102,1	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1344	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2678	115.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2214	2216	GCG	118;126;126	G;C;G,T	102;99;102,1	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1344	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2678	115.9	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2337	2339	GGT	134;134;135	G;G,T;T	116;115,1;116	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1344	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2678	115.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2346	2348	GGC	124;124;124	G,A;G,A;C,G	105,1;103,1;103,1	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1344	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2678	115.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2364	2366	CCG	125;124;123	C,T;C;G,C,T	105,1;107;103,1,1	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1726	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3630	108.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1883	1885	CTG	151;151;151	C,G,T;T,G,A,C;G,C	111,4,2;118,3,1,1;123,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	602	porA	1146	1146	99.65	porA.l6.c4.ctg.1	2557	55.8	0	.	p	.	0	S22G	NONSYN	64	66	AGC	789	791	GGC	73;73;73	G;G;C,T	60;60;60,1	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	602	porA	1146	1146	99.65	porA.l6.c4.ctg.1	2557	55.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	971	971	C	72	C	51	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	T18M	NONSYN	52	54	ACG	503	505	ATG	78;78;79	A;T,C;G	64;66,2;69	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	E41K	NONSYN	121	123	GAA	572	574	AAA	101;101;100	A,G;A;A	88,2;90;89	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	593	595	GGA	92;93;94	G;G;A	80;82;84	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	V75I	NONSYN	223	225	GTT	674	676	ATT	106;106;106	A;T;T	94;93;94	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	T89S	NONSYN	265	267	ACC	716	718	AGC	111;111;112	A,C;G;C	95,1;97;96	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	V98I	NONSYN	292	294	GTC	743	745	ATC	111;111;110	A,C;T;C	96,1;96;98	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	.	MULTIPLE	358	359	AA	808	809	CG	87;86	C;G,A,C	81;73,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	.	MULTIPLE	361	362	GA	811	813	CAG	87;87;87	C;A;G,T	74;74;73,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	N122K	NONSYN	364	366	AAC	815	817	AAA	88;88;88	A,C;A;A,G,C	79,1;82;78,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	842	844	TAT	100;103;102	T,A,G;A,T,C;T,A	89,2,1;93,1,1;83,3	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	N134E	NONSYN	400	402	AAT	851	853	GAG	100;101;101	G,A;A;G,T	84,1;84;84,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	V135F	NONSYN	403	405	GTG	854	856	TTT	100;100;100	T,G,A;T,G;T,G	76,1,1;88,1;88,3	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	G140K	NONSYN	418	420	GGA	869	871	AAA	98;98;99	A,C,G;A,G;A	87,2,1;89,1;90	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	K143E	NONSYN	427	429	AAA	878	880	GAA	98;99;99	G,C;A;A	85,2;88;90	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	V151A	NONSYN	451	453	GTA	902	904	GCA	100;99;98	G;C,T;A,C	87;84,1;84,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	T213S	NONSYN	637	639	ACA	1088	1090	TCA	107;110;109	T,G,C;C,T;A	94,2,1;98,1;98	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1208	1210	CAA	112;112;114	C,T;A,C;A	94,1;94,1;95	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	.	INDELS	760	762	ACA	1212	1216	ATCAA	113;112;111;110;110	A;T,A;C;A;A	94;92,1;92;91;91	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	.	INDELS	763	764	TG	1219	1221	AGT	108;108;108	A;G;T,C,G	86;90;85,2,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1226	1228	GAT	110;109;110	G;A,C;T	91;91,1;93	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	T269S	NONSYN	805	807	ACC	1262	1264	AGC	115;115;116	A;G,C;C	92;95,1;96	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1334	1336	AGT	121;125;121	A;G,T;T,G	109;110,1;106,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1340	1342	GAC	120;120;121	G;A;C	107;107;107	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1343	1345	TAC	120;118;121	TA,T;A;C	105,1;105;107	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	1	SNP	p	G120K	1	.	.	358	360	AAG	808	810	CGG	87;86;86	C;G,A,C;G	81;73,1,1;73	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	1	SNP	p	A121D	1	.	.	361	363	GAC	811	814	CGC	87;87;88	C;G,T;C,A	74;73,1;81,1	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	1041	96.09	porB1b.l6.c4.ctg.1	2137	72.1	1	SNP	p	D121N	0	.	.	361	363	GAC	811	814	CGC	87;87;88	C;G,T;C,A	74;73,1;81,1	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	419	92.4	porB1b.l6.c4.ctg.2	683	0.2	0	.	p	.	0	E41K	NONSYN	121	123	GAA	56	58	AAA	2;2;2	A;A;A	0;0;0	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	419	92.4	porB1b.l6.c4.ctg.2	683	0.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	77	79	GGA	2;2;2	G;G;A	0;0;0	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	527	654	porB1b	1041	419	92.4	porB1b.l6.c4.ctg.2	683	0.2	0	.	p	.	0	K59fs	FSHIFT	175	175	A	110	110	A	ND	ND	ND	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	3822	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5543	161.5	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2349	2351	CAT	198;198;198	C,G;A;T,C	178,1;178;176,2	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	410	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1922	52.2	1	SNP	p	V57M	1	.	.	169	171	ATG	981	983	ATG	118;118;118	A;T;G	101;104;104	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
